Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases

Modern Rheumatology

Volumn 24, Issue 1, 2014, Pages 52-59

  Ito, Satoshi ^a,b   Ogishima, Hiroshi ^a   Kondo, Yuya ^a   Sugihara, Makoto ^a   Hayashi, Taichi ^a   Chino, Yusuke ^a   Goto, Daisuke ^a   Matsumoto, Isao ^a   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Niigata Rheumatic Center   (Japan)

Author keywords

Acarbose; Divided dose administration of prednisolone; Nateglinide; Postprandial hyperglycemia; Steroid induced diabetes mellitus

Indexed keywords

ACARBOSE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; NATEGLINIDE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EARLY DIAGNOSIS; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; OUTPATIENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ACARBOSE; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD GLUCOSE; CONNECTIVE TISSUE DISEASES; CYCLOHEXANES; DIABETES MELLITUS; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHENYLALANINE; PREDNISOLONE; TREATMENT OUTCOME;

EID: 84904999424     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.852855     Document Type: Article

References (26)

1. Guedes C, Dumont-Fischer D, Leichter-Nakache S, Boissier MC. Mortality in rheumatoid arthritis. Rev Rhum. 1999;66:492-8.
2. del Rinccon I, Willams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-45.
3. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13:345-51.
4. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008;35: 2152-8.
5. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308.
6. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-83.
7. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-4.
8. The DECODE Study Group (on behalf of the European Diabetes Epidemiology Group). Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet. 1999;354:617-21.
9. Campbell IW. Nateglinide-current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract. 2005;59:1218-28.
10. Tentolouris N, Voulgari C, Katsilambros N. A review of nateglinide in the management of patients with type 2 diabetes. Vasc Health Risk Manag. 2007;3:797-807.
11. Goke B, Herrmann-Rinke C. The evolving role of alpha-glucosidase inhibitors. Diabetes/Metab Res Rev. 1998;14:S31-8.
12. Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am. 1997;26:539-51.
13. Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105:c54-7.
14. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Clevel Clin J Med. 2011;78:748-56.
15. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-94.
16. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900-8.
17. WHO. Report of a WHO consultation: definition, diagnosis and classification of diabetes mellitus and its complications. Part Diagnosis and classification of diabetes mellitus. Geneva: Department of Noncommunicable Disease Surveillance, World Health Organization; 1999.
18. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96:1789-96.
19. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385-94.
20. Ishida T. Steroid diabetes (in Japanese). Diabetes Frontier. 2007-8;18:332-5.
21. Kondo Y, Ito S, Ogishima H, Sugihara M, Umeda N, Horikoshi M, et al. Early diagnosis of steroid diabetes using 1,5-Anhydro-Dglycitol and good control for blood sugar. Presented at: 52nd Scientific Meeting of Japan College of Rheumatology; 2008 April 20-23; Sapporo, Japan. P3-440.
22. Miwa S, Watada H, Ohmura C, Tanaka Y, Kawamori R. Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide. Endocr J. 2004;51:393-8.
23. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes/Metab Res Rev. 2001;17:467-73.
24. Nakajima A, Doki K, Homma M, Sagae T, Saito R, Ito S, et al. Investigation of glucocorticoid-induced side effect in patients with autoimmune disease (in Japanese). Yakugai Zassi. 2009;129:445-50.
25. Yanai H, Masui Y, Yoshikawa R, Kunimatsu J, Kaneko H. Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes. World J Diabetes (China). 2010;1:99-100.
26. Ito S. Steroid induced diabetes mellitus (in Japanese). In: Diagnosis and treatment of adverse effects of drugs/development of new drugs. Technical Information Institute. Tokyo; 2012. p. 443-4.